Shares of MiniMed Group Inc (NASDAQ:MMED – Get Free Report) have received an average recommendation of “Moderate Buy” from the nineteen brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $24.12.
Several research analysts have recently issued reports on the company. Morgan Stanley increased their target price on MiniMed Group from $19.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday, September 3rd. Jefferies Financial Group assumed coverage on MiniMed Group in a research note on Monday, October 12th. They issued a “hold” rating and a $22.00 target price for the company. Barclays dropped their price target on MiniMed Group from $22.00 to $20.00 and set an “equal weight” rating on the stock in a research report on Friday, November 13th. Weiss Ratings raised MiniMed Group from a “sell (d-)” rating to a “sell (d)” rating in a research note on Wednesday, September 9th. Finally, Wells Fargo & Company increased their price objective on MiniMed Group from $22.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday, September 2nd.
Check Out Our Latest Report on MiniMed Group
MiniMed Group Price Performance
Shares of MMED opened at $17.78 on Wednesday. MiniMed Group has a one year low of $10.65 and a one year high of $24.43. The company has a 50-day simple moving average of $19.40 and a two-hundred day simple moving average of $16.75. The firm has a market capitalization of $5.00 billion and a PE ratio of -26.15.
Institutional Trading of MiniMed Group
Hedge funds and other institutional investors have recently modified their holdings of the business. Parkside Financial Bank & Trust purchased a new position in MiniMed Group during the 2nd quarter valued at about $28,000. Boston Partners boosted its stake in MiniMed Group by 0.6% during the third quarter. Boston Partners now owns 908,007 shares of the company’s stock worth $17,695,000 after acquiring an additional 5,648 shares in the last quarter. Legal & General Group Plc bought a new stake in MiniMed Group during the second quarter worth about $91,000. State of Wyoming bought a new stake in MiniMed Group during the third quarter worth about $167,000. Finally, New York State Common Retirement Fund purchased a new stake in MiniMed Group in the third quarter worth about $197,000.
MiniMed Group Company Profile
MiniMed Group focuses on diabetes technology, developing products and services to help people manage insulin-dependent diabetes. Its offerings include insulin pumps, continuous glucose monitoring systems, infusion sets and software for tracking glucose and coordinating insulin delivery. The business is known for automated insulin-delivery systems that use glucose readings to help adjust insulin delivery, including products in the MiniMed 780G system line. Its technologies are intended for use by people with diabetes and the clinicians who support their care.
Featured Stories
- Five stocks we like better than MiniMed Group
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for MiniMed Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiniMed Group and related companies with MarketBeat.com's FREE daily email newsletter.
